System and method for venous pulsation detection using near infrared wavelengths

Information

  • Patent Grant
  • 8109882
  • Patent Number
    8,109,882
  • Date Filed
    Friday, March 9, 2007
    17 years ago
  • Date Issued
    Tuesday, February 7, 2012
    12 years ago
Abstract
Methods and systems for detecting venous pulsation are provided. In accordance with an exemplary embodiment of the present technique, there is provided a method for detecting venous pulsation, including acquiring a first signal corresponding to absorption at a first near-infrared wavelength, acquiring a second signal corresponding to absorption at a second near-infrared wavelength, deriving an offset metric from the first and second signals, and detecting the presence of venous pulsation based on the offset metric. The method further includes correcting calculations of physiological parameters such as, for example, blood oxygen saturation, when venous pulsation is detected.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The present invention relates to pulse oximetry. More particularly, embodiments of the present invention relate to processing of signals generated by a pulse oximeter.


2. Description of the Related Art


This section is intended to introduce the reader to various aspects of art that may be related to various aspects of the present invention, which are described and/or claimed below. This discussion is believed to be helpful in providing the reader with background information to facilitate a better understanding of the various aspects of the present invention. Accordingly, it should be understood that these statements are to be read in this light, and not as admissions of prior art.


In the field of medicine, doctors often desire to monitor certain physiological characteristics of their patients. Accordingly, a wide variety of devices have been developed for monitoring many such physiological characteristics. Such devices provide doctors and other healthcare personnel with the information they need to provide the best possible healthcare for their patients. As a result, such monitoring devices have become an indispensable part of modern medicine.


One technique for monitoring certain physiological characteristics of a patient is commonly referred to as pulse oximetry, and the devices built based upon pulse oximetry techniques are commonly referred to as pulse oximeters. Pulse oximetry may be used to measure various blood flow characteristics, such as the blood oxygen saturation of hemoglobin in arterial blood, the volume of individual blood pulsations supplying the tissue, and/or the rate of blood pulsations corresponding to each heartbeat of a patient. In fact, the “pulse” in pulse oximetry refers to the time-varying amount of arterial blood in the tissue during each cardiac cycle.


Pulse oximeters typically utilize a non-invasive sensor that transmits light through a patient's tissue and that photoelectrically detects the absorption and/or scattering of the transmitted light in such tissue. One or more of the above physiological characteristics may then be calculated based upon the amount of light absorbed or scattered. More specifically, the light passed through the tissue is typically selected to be of one or more wavelengths that may be absorbed or scattered by the blood in an amount correlative to the amount of the blood constituent present in the blood. The amount of light absorbed and/or scattered may then be used to estimate the amount of blood constituent in the tissue using various algorithms.


Sensors exist that are designed to be applied to a patient's forehead. However, a phenomenon called “venous pulsation” may occur in the forehead or other sites that are not on the patient's extremities and cause incorrect sensor readings. Venous pulsation refers to a pulse generated from the return flow of venous blood to the heart. Because the hemoglobin in venous blood has already delivered oxygen to tissue, and due to prominent harmonics in a venous pressure wave, sensor readings based on venous pulsation may result in artificially low calculations of blood oxygen saturation. In addition, pulse rate calculations based on incorrect sensor readings may be double or triple the patient's actual pulse rate.


While the reliability of traditional pulse oximetry techniques may be adversely impacted by artifacts caused by venous pulsation, traditional techniques may fail to recognize venous pulsation as the source of an error. In some cases, physiological parameters may be calculated in the presence of venous pulsation for hours without any indication that the resulting values are incorrect.


SUMMARY

Certain aspects commensurate in scope with the originally claimed invention are set forth below. It should be understood that these aspects are presented merely to provide the reader with a brief summary of certain forms the invention might take and that these aspects are not intended to limit the scope of the invention. Indeed, the invention may encompass a variety of aspects that may not be set forth below.


There is provided a method for detecting venous pulsation, including acquiring a first signal corresponding to absorption at a first near-infrared wavelength, acquiring a second signal corresponding to absorption at a second near-infrared wavelength, deriving an offset metric from the first and second signals, and detecting the presence of venous pulsation based on the offset metric.


There is further provided a device for detecting venous pulsation, including a monitor configured to acquire a first signal corresponding to absorption at a first near-infrared wavelength and a second signal corresponding to absorption at a second near-infrared wavelength, derive an offset metric from the first and second signals, and detect the presence of venous pulsation based on the offset metric.


There is further provided a system for detecting venous pulsation, including a sensor configured to emit light at three or more wavelengths into a patient's tissue and detect absorption of the light, and a monitor configured to acquire a first signal corresponding to absorption at a first near-infrared wavelength and a second signal corresponding to absorption at a second near-infrared wavelength, derive an offset metric from the first and second signals, and detect the presence of venous pulsation based on the offset metric.


There is further provided a method of manufacturing a device for detecting venous pulsation, including providing a monitor configured to acquire a first signal corresponding to absorption at a first near-infrared wavelength and a second signal corresponding to absorption at a second near-infrared wavelength, derive an offset metric from the first and second signals, and detect the presence of venous pulsation based on the offset metric.





BRIEF DESCRIPTION OF THE DRAWINGS

Advantages of the invention may become apparent upon reading the following detailed description and upon reference to the drawings in which:



FIG. 1 is a perspective view of a pulse oximetry monitor coupled to a multi-parameter patient monitor and a sensor in accordance with an exemplary embodiment of the present invention;



FIG. 2 illustrates a sensor applied to a patient's forehead in accordance with an exemplary embodiment of the present invention;



FIG. 3 is a block diagram of a pulse oximetry system coupled to a patient in accordance with an exemplary embodiment of the present invention;



FIG. 4 includes four graphs showing plots of results obtained in detecting venous pulsations in each of four subjects; and



FIG. 5 is a flow chart of a process related to detecting venous pulsations in accordance with an exemplary embodiment of the present invention.





DETAILED DESCRIPTION OF SPECIFIC EMBODIMENTS

One or more specific embodiments of the present invention will be described below. In an effort to provide a concise description of these embodiments, not all features of an actual implementation are described in the specification. It should be appreciated that in the development of any such actual implementation, as in any engineering or design project, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which may vary from one implementation to another. Moreover, it should be appreciated that such a development effort might be complex and time consuming, but would nevertheless be a routine undertaking of design, fabrication, and manufacture for those of ordinary skill having the benefit of this disclosure.


Embodiments of the present invention relate to detecting the presence of venous pulsation, when using a forehead pulse oximetry sensor for example, and correcting the errors associated with venous pulsation in calculating a patient's physiological parameters, such as blood oxygen saturation and pulse rate. Specifically, in accordance with present embodiments, a sensor emits and detects a near-infrared wavelength of light in addition to the red and near-infrared wavelengths commonly used to calculate physiological parameters. This third wavelength of light is used to determine whether venous pulsation is occurring and to correct measurements of the commonly used red and near-infrared wavelengths of light when venous pulsation occurs.


In accordance with an exemplary embodiment of the present invention, arterial blood oxygen saturation, commonly denoted as SaO2, may be estimated as a ratio of oxygenated hemoglobin (HbO2) to deoxygenated hemoglobin (Hb) present in a patient's tissue. Hemoglobin is the component of blood which transports oxygen throughout the body. The ratio of HbO2 to Hb can be determined by shining light at certain wavelengths into a patient's tissue and measuring the absorbance of the light. A first wavelength is typically selected at a point in the electromagnetic spectrum where the absorption of HbO2 differs from the absorption of reduced Hb, and a second wavelength is typically selected at a different point in the spectrum where the absorption of Hb and HbO2 differs from those at the first wavelength. For example, wavelength selections for measuring normal blood oxygenation levels typically include a red light emitted at approximately 660 nm and a near-infrared light emitted at approximately 900 nm, although other red and near-infrared wavelengths may be used. A yellow or orange wavelength may be utilized instead of, or in addition to, the red wavelength.


One common technique for estimating SaO2 is to calculate a characteristic known as the ratio-of-ratios (Ratrat) of the absorption of the red light (RED) to the near-infrared light (IR). While various techniques may be utilized to calculate Ratrat, in one common technique in accordance with an exemplary embodiment of the present invention, a sensor is used to emit red and near-infrared light into a patient's tissue and detect the light that is reflected back. Signals indicative of the detected light are conditioned and processed to generate plethysmographs of the detected light over time. A plethysmographic waveform is generally periodic, with a shape between that of a sawtooth and a sinusoid, having both an AC and a DC component. These AC and DC components may be estimated from maximum (MAX) and minimum (MIN) points in a cycle of the waveform, according to the following equations:

AC=MAX−MIN,  (1)
DC=(MAX+MIN)/2.  (2)


It should be noted that in other embodiments the maximum and minimum measurements are not necessarily employed to determine the AC and DC components. Indeed, the AC and DC components may be obtained by using essentially any pair of points along both the red and near-infrared light waveforms. The AC and DC components of the RED wavelength and IR wavelength signals may then be used to calculate Ratrat according to the following equation:









Ratrat
=




AC
RED

/

DC
RED




AC
IR

/

DC
IR



.





(
3
)








Ratrat has been observed to correlate well to SaO2. This observed correlation is used to estimate SaO2 based on the measured value of the ratio-of-ratios. This pulse-based estimate of SaO2 is commonly denoted as SpO2.



FIG. 1 is a perspective view of a pulse oximetry system 10 in accordance with an exemplary embodiment of the present invention. The system 10 may include a pulse oximetry monitor 12 and a sensor 14. The monitor 12 may be configured to calculate values for physiological parameters, as described below, and to display physiological parameters and/or other information about the system on a display 16. The sensor 14 may include an emitter 18 for emitting light at certain wavelengths into a patient's tissue and a detector 20 for detecting the light after it is scattered and reflected by the patient's tissue. The sensor 14 may be communicatively coupled to the monitor 12 via a cable 22 or other suitable means, such as, for example, a wireless transmission device (not shown).


The pulse oximetry system 10 may also include a multi-parameter patient monitor 24. The multi-parameter patient monitor 24 may be included in the system 10 to provide a central display for information from the monitor 12 and from other medical monitoring devices or systems (not shown). For example, the multi-parameter patient monitor 24 may display a patient's blood oxygen saturation and pulse rate information from the monitor 12 and blood pressure from a blood pressure monitor (not shown). In addition to the monitor 12, or alternatively, the multi-parameter patient monitor 24 may be configured to calculate values for physiological parameters, as described below. The monitor 12 may be communicatively coupled to the multi-parameter patient monitor 24 via a cable 26 or 28 coupled to a sensor input port or a digital communications port, respectively.



FIG. 2 illustrates the sensor 14 applied to a patient's forehead 30 in accordance with an exemplary embodiment of the present invention. The sensor 14 may include components to facilitate venous pulsation detection and/or compensation for related measurement errors as set forth below. Venous pulsation is more likely to occur when the sensor 14 is applied to a patient's forehead 30 as illustrated, without any external pressure applied to the sensor site. A headband (not shown) may be placed over the sensor 14 to reduce the effects of venous pulsation on the calculation of a patient's physiological parameters.



FIG. 3 is a block diagram of the pulse oximetry system 10 in accordance with an exemplary embodiment of the present invention. Components of the monitor 12 and the sensor 14 are illustrated. The sensor 14 includes emitter 18, detector 20, and an encoder 32. Furthermore, emitter 18 is configured to emit at least three wavelengths of light. Monitor 12 includes a processor 34, a memory 36, and display 16.


In accordance with an exemplary embodiment of the present invention, the emitter 18 includes a RED LED 38, an IR LED 40, and an IRHb LED 42 for emitting light at the wavelengths required to calculate values for physiological parameters, as described below. Alternative light sources may be used in other embodiments of the present invention. For example, a single wide-spectrum light source may be used, and the detector 20 may be configured to detect light only at certain wavelengths. Alternatively, the detector 20 may detect a wide spectrum of wavelengths of light, and the monitor 12 may process only those wavelengths which are of interest. The emitter 18 may shine light at the different wavelengths into the patient's forehead tissue 30.


The detector 20 may be configured to detect the intensity of light at the RED, IR, and IRHb wavelengths in accordance with an exemplary embodiment of the present invention. Light enters the detector 20 after reflecting off tissue in the patient's forehead 30. The detector 20 may measure the intensity of light at each wavelength of interest and convert that measurement into a digital signal. The light intensity is directly related to the absorbance of light in the tissue 30. That is, when more light at a certain wavelength is absorbed, less light of that wavelength is reflected back and detected by the detector 20. After measuring the light and converting it to a digital signal, the detector 20 may send the signal to the monitor 12.


The encoder 32 may contain information about the wavelengths of light emitted by the emitter 18. This information may allow the monitor 12 to select appropriate calibration coefficients for calculating the patient's physiological parameters. The encoder 32 may, for instance, be a resistor. In addition, the encoder 32 may include information about the sensor 14, such as, for example, that it is a forehead sensor. Any information the encoder 32 contains may be communicated to the monitor 12 for processing along with the information about the detected light from detector 20.


The processor 34 in the monitor 12 may be configured to process incoming signals from and send control signals to the sensor 14. Intermediate hardware (not shown) may be included in the monitor 12 to filter or convert incoming signals and to implement outgoing controls. The memory 36 may contain programming to enable processor 34 to calculate values for physiological parameters, as described below, and to implement the process described below in relation to FIG. 5. In addition, results of such calculations may be stored on the memory 36 and/or displayed on the display 16. The display 16 may also provide a visual notification of the presence of venous pulsation when detected.


Recent trials were run in which wide spectrum light was shone into subjects' forehead tissues and the reflectance/absorbance was detected. It was observed from analysis of these trials that the AC signal contains a generally wavelength-independent offset which does not appear to correlate with light absorption in principal blood or tissue components that are typically intended to be measured. This offset was much higher when the subjects were placed in a position in which venous pulsation was likely to occur than when they were not. The addition of a positive wavelength-independent offset to the AC amplitude causes the Ratrat to converge towards a value near 1.0, regardless of the actual SaO2. For typical pulse-oximetry wavelengths, a Ratrat of 1.0 corresponds to an SaO2 near 80%, while a normal adult breathing room air has an SaO2 near 97%. These wavelength-independent offsets in AC amplitude may cause biases in the SpO2 calculation, which are often seen when venous pulsation is present.


The plots shown in FIG. 4 are a graphic illustration of the results of trials testing the detection of venous pulsation in four subjects. In the trials, subjects were monitored using forehead sensors as they were placed into erect positions (i.e., head above heart) and Trendelenburg positions (i.e., heart above head). The Trendelenburg position has been observed to cause venous pulsation in the forehead when no steps are taken to prevent this phenomenon. This data was collected with a sensor having an emitter-detector separation of approximately 2.5 mm. The ratio-of-ratios was calculated for a near-infrared wavelength at which hemoglobin has a low absorption (IRHb) to the near-infrared wavelength used to estimate SpO2 (IR), as illustrated in the following equation:










Ratrat
Hb

=




AC
IRHb

/

DC
IRHb




AC
IR

/

DC
IR



.





(
4
)








The calculated RatratHb was found to correlate to the presence of venous pulsation.


At wavelengths where hemoglobin has a low absorption, the AC offset is expected to be primarily due to the effects of venous pulsation. Hemoglobin has a sufficiently low absorption at a wavelength in the range of 1,050-1,350 nm. Due to local water and blood pooling, changes in the water component of the AC spectrum were also observed in some subjects. So that these water changes do not confound the detection of venous pulsation, it may be desirable to further narrow the wavelength range to about 1,050-1,160 nm. FIG. 4 illustrates RatratHb calculated where IRHb is 1,126 nm and IR is 918 nm.


In the graphs illustrated in FIG. 4, the RatratHb of the selected wavelengths are plotted on the y-axis 50 against time on the x-axis 52. Data points 54 represent the calculated RatratHb when a subject was in an erect position, and data points 56 represent the calculated RatratHb when a subject was in the Trendelenburg position. When pressure is not applied to a forehead sensor, as in these trials, it can be assumed that placing a subject in the Trendelenburg position will cause venous pulsation. As can be seen from the graphs in FIG. 4, the RatratHb was substantially higher for each subject when venous pulsation was likely to be present (data points 56) than when it was not (data points 54). In addition, the RatratHb was generally consistent when venous pulsation was not likely to be present (data points 54), as illustrated by trendline 58.


As a result of these studies, an offset metric may be derived to predict the presence of venous pulsation in subjects with more accuracy than that seen with previous methods of detecting venous pulsation. This offset metric may be the RatratHb itself or a change in RatratHb from historical values (ΔRatratHb). FIG. 5 is a flow chart of a process 60 in accordance with an exemplary embodiment of the present invention. In this process 60, the presence of venous pulsation is detected based on the offset metric.


As illustrated in FIG. 5, at least two digital near-IR waveforms 62 are provided. These waveforms 62 correspond to detected light at the IR and IRHb wavelengths. The RatratHb is calculated (Block 64) for IRHb to IR, for example, as described above in Eq. 4. A current RatratHb 66 may be compared (Block 70) to historical values 68 of RatratHb. The historical values 68 may include actual values calculated from a given patient or average values calculated from other subjects. In an exemplary embodiment of the present invention, the process 60 may use average values as the historical values 68. Once enough data has been collected to provide a reliable baseline for an individual patient, that patient's actual measurement data may be utilized as the historical values 68. In addition, the historical values 68 may be represented as an average, weighted average, mean, median, or mode.


An offset metric 72 may be derived from the current RatratHb 66 and the historical values 68. This offset metric 72 may be the difference between the current RatratHb 66 and the historical values 68, denoted ΔRatratHb, the current RatratHb 66, or a combination thereof. The offset metric 72 may be compared to a threshold 74 to determine if the threshold 74 is exceeded (Block 76). Threshold 74 may be a pre-determined value or may be based on the historical values 68 of the RatratHb. For example, in accordance with an exemplary embodiment of the present invention, threshold 74 may be a fixed value for all patients above which venous pulsation is expected to be present. Alternatively, threshold 74 may be a fixed value based on a patient's physical characteristics, such as, for example, sex, weight, race, and age. In accordance with another embodiment, threshold 74 may be a change from a patient's actual historical values 68. That is, threshold 74 may be a fixed value or percentage above a baseline of a patient's historical values 68.


If the offset metric 72 exceeds the threshold 74, the presence of venous pulsation may be reported (Block 78). Reporting venous pulsation (Block 78) may include any suitable method, such as, for example, displaying an error message, sounding an audible alarm, or ceasing display of physiological parameters. Alternatively, or in addition to reporting the presence of venous pulsation (Block 78), corrections may be made in the calculation of other physiological parameters (Block 80) based on the measured AC offset. For example, the AC offset detected in the IRHb wavelength may be corrected for the RED and IR wavelengths by subtracting it from the AC measurements at those wavelengths before physiological parameters are calculated.


If the offset metric 72 does not exceed the threshold 74, the presence of venous pulsation may not be reported (Block 82). Regardless of the outcome of the comparison (Block 76) of the offset metric 72 to the threshold 74, the process 60 continues by returning to the calculation of RatratHb (Block 64) for new detected measurements of IR and IRHb.


While the invention may be susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and have been described in detail herein. However, it should be understood that the invention is not intended to be limited to the particular forms disclosed. Indeed, the but these techniques may not only be applied to measurements of blood oxygen saturation, but these techniques may also be utilized for the measurement and/or analysis of other blood constituents. For example, using the same, different, or additional wavelengths, the present techniques may be utilized in conjunction with the measurement and/or analysis of carboxyhemoglobin, met-hemoglobin, total hemoglobin, intravascular dyes, and/or water content. The invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the following appended claims.

Claims
  • 1. A method for detecting venous pulsation, comprising: acquiring a first signal corresponding to absorption at a first near-infrared wavelength from a sensor;acquiring a second signal corresponding to absorption at a second near-infrared wavelength from the sensor;deriving an offset metric from the first and second signals with a processor, wherein the offset metric comprises a difference between current and historical values of a ratio-of-ratios of the absorption at the first near-infrared wavelength to the absorption at the second near-infrared wavelength; anddetecting the presence of venous pulsation based on comparing the offset metric with a threshold value and determining whether the offset metric exceeds the threshold value using the processor.
  • 2. The method of claim 1, comprising providing, with a monitor, a notification of the presence of venous pulsation when detected.
  • 3. The method of claim 1, comprising acquiring a third signal corresponding to absorption at a third wavelength from the sensor and calculating a physiological parameter with the processor based on the second and third signals.
  • 4. The method of claim 3, comprising correcting, with the processor, the calculation of the physiological parameter by subtracting an AC offset of the third signal from an AC measurement of the second signal utilized in the calculation of the physiological parameter.
  • 5. The method of claim 3, wherein the second near-infrared wavelength comprises a wavelength of about 900 nm and wherein the third wavelength comprises a wavelength of about 660 nm.
  • 6. The method of claim 1, wherein the first near-infrared wavelength comprises a wavelength in a range of 1,050 to 1,350 nm where hemoglobin has a lower absorption than at the second near-infrared wavelength, which comprises a wavelength of approximately 900 nm.
  • 7. The method of claim 6, wherein the wavelength of approximately 900 nm is 918 nm.
  • 8. The method of claim 1, wherein the first near-infrared wavelength comprises a wavelength from 1,050 to 1,350 nm.
  • 9. The method of claim 1, wherein the first near-infrared wavelength comprises a wavelength from 1,050 to 1,160 nm.
  • 10. The method of claim 1, wherein the threshold value comprises at least one of a fixed value or a value based on a plurality of historic ratios-of-ratios.
  • 11. A device for detecting venous pulsation, comprising: a monitor configured to: acquire a first signal corresponding to absorption at a first near-infrared wavelength and a second signal corresponding to absorption at a second near-infrared wavelength;derive an offset metric from the first and second signals, wherein the offset metric comprises a difference between current and historical values of a ratio-of-ratios of the absorption at the first near-infrared wavelength to the absorption at the second near-infrared wavelength; anddetect the presence of venous pulsation based on comparing the offset metric with a threshold value and determining whether the offset metric exceeds the threshold value.
  • 12. The device of claim 11, wherein the monitor is configured to provide a notification of the presence of venous pulsation when detected.
  • 13. The device of claim 11, wherein the monitor is configured to acquire a third signal corresponding to absorption at a third wavelength and to calculate a physiological parameter based on the second and third signals.
  • 14. The device of claim 13, wherein the monitor is configured to correct the calculation of the physiological parameter by subtracting an AC offset of the third signal from an AC measurement of the second signal utilized in the calculation of the physiological parameter.
  • 15. A system for detecting venous pulsation, comprising: a sensor configured to: emit light at three or more wavelengths into a patient's tissue; and detect absorption of the light; anda monitor configured to:acquire a first signal from the sensor corresponding to absorption at a first near-infrared wavelength and a second signal from the sensor corresponding to absorption at a second near-infrared wavelength;derive an offset metric from the first and second signals, wherein the offset metric comprises a difference between current and historical values of a ratio-of-ratios of the absorption at the first near-infrared wavelength to the absorption at the second near-infrared wavelength; anddetect the presence of venous pulsation based on comparing the offset metric with a threshold value and determining whether the offset metric exceeds the threshold value.
  • 16. The system of claim 15, wherein the first near-infrared wavelength comprises a wavelength in a range of 1,050 to 1,350 nm where hemoglobin has a lower absorption than at the second near-infrared wavelength, which comprises a wavelength of approximately 900 nm.
  • 17. The system of claim 16, wherein the wavelength of approximately 900 nm is 918 nm.
  • 18. The device of claim 15, wherein the three or more wavelengths comprise about 660 nm, about 900 nm, and about 1,126 nm.
  • 19. The device of claim 15, wherein the monitor is configured to provide a notification of the presence of venous pulsation when detected.
  • 20. The device of claim 15, wherein the monitor is configured to acquire a third signal corresponding to absorption at a red wavelength from the sensor and to calculate a physiological parameter based on the second and third signals.
  • 21. The device of claim 20, wherein the monitor is configured to correct the calculation of the physiological parameter by subtracting an AC offset of the third signal from an AC measurement of the second signal utilized in the calculation of the physiological parameter.
US Referenced Citations (217)
Number Name Date Kind
3998550 Konishi et al. Dec 1976 A
4066068 Nilsson et al. Jan 1978 A
4364008 Jacques Dec 1982 A
4380439 Kreitenberg Apr 1983 A
4711244 Kuzara Dec 1987 A
4723554 Oman et al. Feb 1988 A
4759369 Taylor Jul 1988 A
4805623 Jobsis Feb 1989 A
4824242 Frick et al. Apr 1989 A
4850365 Rosenthal Jul 1989 A
4859057 Taylor et al. Aug 1989 A
4860753 Amerena Aug 1989 A
4863265 Flower et al. Sep 1989 A
4867557 Takatani et al. Sep 1989 A
4883055 Merrick Nov 1989 A
4907594 Muz Mar 1990 A
4911167 Corenman et al. Mar 1990 A
4926867 Kanda et al. May 1990 A
4955379 Hall Sep 1990 A
4968137 Yount Nov 1990 A
5025791 Niwa Jun 1991 A
5057695 Hirao et al. Oct 1991 A
5086781 Bookspan Feb 1992 A
5111817 Clark et al. May 1992 A
5146091 Knudson Sep 1992 A
5224478 Sakai et al. Jul 1993 A
5251632 Delpy Oct 1993 A
5263244 Centa et al. Nov 1993 A
5267562 Ukawa et al. Dec 1993 A
5267563 Swedlow et al. Dec 1993 A
5277181 Mendelson et al. Jan 1994 A
5278627 Aoyagi et al. Jan 1994 A
5279295 Martens et al. Jan 1994 A
5282467 Piantadosi et al. Feb 1994 A
5297548 Pologe Mar 1994 A
5299120 Kaestle Mar 1994 A
5329922 Atlee, III Jul 1994 A
5337745 Benaron Aug 1994 A
5337937 Blank et al. Aug 1994 A
5348004 Hollub Sep 1994 A
5348005 Merrick et al. Sep 1994 A
5349519 Kaestle Sep 1994 A
5355880 Thomas et al. Oct 1994 A
5355882 Ukawa et al. Oct 1994 A
5377674 Kuestner Jan 1995 A
5390670 Centa et al. Feb 1995 A
5392777 Swedlow et al. Feb 1995 A
5396893 Oberg et al. Mar 1995 A
5402777 Warring et al. Apr 1995 A
5402778 Chance Apr 1995 A
5408998 Mersch Apr 1995 A
5417207 Young et al. May 1995 A
5458562 Cooper Oct 1995 A
5485847 Baker, Jr. Jan 1996 A
5490505 Diab et al. Feb 1996 A
5499627 Steuer et al. Mar 1996 A
5503148 Pologe et al. Apr 1996 A
5517988 Gerhard May 1996 A
5522388 Ishikawa et al. Jun 1996 A
5524617 Mannheimer Jun 1996 A
5575285 Takanashi et al. Nov 1996 A
5584299 Sakai et al. Dec 1996 A
5595176 Yamaura Jan 1997 A
5615689 Kotler Apr 1997 A
5645059 Fein et al. Jul 1997 A
5662106 Swedlow et al. Sep 1997 A
5685299 Diab et al. Nov 1997 A
5687721 Kuhls Nov 1997 A
5690104 Kanemoto et al. Nov 1997 A
5701902 Vari et al. Dec 1997 A
5715816 Mainiero et al. Feb 1998 A
5720284 Aoyagi et al. Feb 1998 A
5735284 Tsoglin et al. Apr 1998 A
5743261 Mainiero et al. Apr 1998 A
5743263 Baker, Jr. Apr 1998 A
5743349 Steinberg Apr 1998 A
5746206 Mannheimer May 1998 A
5747789 Godik May 1998 A
5755672 Arai et al. May 1998 A
5766127 Pologe et al. Jun 1998 A
5788643 Feldman Aug 1998 A
5803908 Steuer et al. Sep 1998 A
5810723 Aldrich Sep 1998 A
5817008 Rafert et al. Oct 1998 A
5827181 Dias et al. Oct 1998 A
5830137 Scharf Nov 1998 A
5833602 Osemwota Nov 1998 A
5853364 Baker, Jr. et al. Dec 1998 A
5860919 Kiani-Azarbayjany et al. Jan 1999 A
5871694 Beden et al. Feb 1999 A
5891025 Buschmann et al. Apr 1999 A
5902235 Lewis et al. May 1999 A
5906582 Kondo et al. May 1999 A
5934277 Mortz Aug 1999 A
6018673 Chin et al. Jan 2000 A
6064898 Aldrich May 2000 A
6073041 Hu et al. Jun 2000 A
6125297 Siconolfi Sep 2000 A
6149591 Henderson et al. Nov 2000 A
6149597 Kamiyama Nov 2000 A
6151107 Schollermann et al. Nov 2000 A
6151518 Hayashi Nov 2000 A
6178342 Thompson et al. Jan 2001 B1
6178343 Bindszus et al. Jan 2001 B1
6216021 Franceschini et al. Apr 2001 B1
6222189 Misner et al. Apr 2001 B1
6230035 Aoyagi et al. May 2001 B1
6246894 Steuer et al. Jun 2001 B1
6258038 Haryadi et al. Jul 2001 B1
6263222 Diab et al. Jul 2001 B1
6272363 Casciani et al. Aug 2001 B1
6278889 Robinson Aug 2001 B1
6280396 Clark et al. Aug 2001 B1
6285896 Tobler et al. Sep 2001 B1
6299583 Eggers et al. Oct 2001 B1
6330468 Scharf Dec 2001 B1
6334065 Al-Ali et al. Dec 2001 B1
6336044 Ghiassi et al. Jan 2002 B1
6339715 Bahr et al. Jan 2002 B1
6370426 Campbell et al. Apr 2002 B1
6374129 Chin et al. Apr 2002 B1
6381480 Stoddart et al. Apr 2002 B1
6385471 Mortz May 2002 B1
6393310 Kuenstner May 2002 B1
6393311 Edgar, Jr. et al. May 2002 B1
6397093 Aldrich May 2002 B1
6400971 Finarov et al. Jun 2002 B1
6402690 Rhee et al. Jun 2002 B1
6406267 Mondiere Jun 2002 B1
6411832 Guthermann Jun 2002 B1
6415236 Kobayashi et al. Jul 2002 B2
6438399 Kurth Aug 2002 B1
6442408 Wenzel et al. Aug 2002 B1
6449501 Reuss Sep 2002 B1
6461165 Takanashi et al. Oct 2002 B1
6466807 Dobson et al. Oct 2002 B1
6480729 Stone Nov 2002 B2
6488677 Bowman et al. Dec 2002 B1
6494576 L'Esperance Dec 2002 B1
6501974 Huiku Dec 2002 B2
6512936 Monfre et al. Jan 2003 B1
6519486 Edgar, Jr. et al. Feb 2003 B1
6526297 Merilainen Feb 2003 B1
6584336 Ali et al. Jun 2003 B1
6587704 Fine et al. Jul 2003 B1
6591122 Schmitt Jul 2003 B2
6592574 Shimmick et al. Jul 2003 B1
6600946 Rice Jul 2003 B1
6606509 Schmitt Aug 2003 B2
6615064 Aldrich Sep 2003 B1
6615065 Barrett et al. Sep 2003 B1
6622095 Kobayashi et al. Sep 2003 B2
6635491 Khalil et al. Oct 2003 B1
6636759 Robinson Oct 2003 B2
6643543 Takehara et al. Nov 2003 B2
6647280 Bahr et al. Nov 2003 B2
6650917 Diab et al. Nov 2003 B2
6654620 Wu et al. Nov 2003 B2
6668181 Wenzel et al. Dec 2003 B2
6671526 Aoyagi et al. Dec 2003 B1
6675029 Monfre et al. Jan 2004 B2
6687519 Steuer et al. Feb 2004 B2
6702752 Dekker Mar 2004 B2
6714803 Mortz Mar 2004 B1
6714804 Al-Ali et al. Mar 2004 B2
6754515 Pologe Jun 2004 B1
6770028 Ali et al. Aug 2004 B1
6777240 Hazen et al. Aug 2004 B2
6780158 Yarita Aug 2004 B2
6801799 Mendelson Oct 2004 B2
6810277 Edgar, Jr. et al. Oct 2004 B2
6839585 Lowery et al. Jan 2005 B2
6842635 Parker Jan 2005 B1
6845256 Chin et al. Jan 2005 B2
6849046 Eyal-Bickels Feb 2005 B1
6859658 Krug Feb 2005 B1
6879850 Kimball Apr 2005 B2
6898452 Al-Ali et al. May 2005 B2
6947780 Scharf Sep 2005 B2
6947781 Asada Sep 2005 B2
6950699 Manwaring et al. Sep 2005 B1
6970792 Diab Nov 2005 B1
6987994 Mort Jan 2006 B1
7039538 Baker, Jr. May 2006 B2
7194293 Baker, Jr. Mar 2007 B2
7209774 Baker, Jr. Apr 2007 B2
7236811 Schmitt Jun 2007 B2
7239902 Schmitt et al. Jul 2007 B2
7263395 Chan et al. Aug 2007 B2
7277741 Debreczeny et al. Oct 2007 B2
20010020122 Steuer et al. Sep 2001 A1
20030060693 Monfre et al. Mar 2003 A1
20040127777 Ruchti et al. Jul 2004 A1
20040147034 Gore et al. Jul 2004 A1
20040230106 Schmitt et al. Nov 2004 A1
20040249252 Fine et al. Dec 2004 A1
20050197552 Baker, Jr. Sep 2005 A1
20050197579 Baker, Jr. Sep 2005 A1
20050256386 Chan et al. Nov 2005 A1
20060020181 Schmitt Jan 2006 A1
20060084864 Schmitt et al. Apr 2006 A1
20060167350 Monfre et al. Jul 2006 A1
20060200015 Baker, Jr. Sep 2006 A1
20060224053 Black et al. Oct 2006 A1
20060253007 Cheng et al. Nov 2006 A1
20060253016 Baker, Jr. et al. Nov 2006 A1
20060276696 Schurman Dec 2006 A1
20070032714 Mannheimer Feb 2007 A1
20070077200 Baker, Jr. Apr 2007 A1
20070100220 Baker, Jr. May 2007 A1
20070106137 Baker et al. May 2007 A1
20070118027 Baker, Jr. et al. May 2007 A1
20070129614 Schmitt et al. Jun 2007 A1
20070208242 Baker, Jr. Sep 2007 A1
20080077022 Baker Mar 2008 A1
20080221417 Baker et al. Sep 2008 A1
20080221462 Baker Sep 2008 A1
Foreign Referenced Citations (17)
Number Date Country
2353007 Jun 2000 CA
19855521 Jun 2000 DE
1135184 Jun 2000 EP
1184663 Mar 2002 EP
2710517 Apr 1995 FR
4-40940 Feb 1992 JP
5-329163 Dec 1993 JP
11-244266 Sep 1999 JP
2004 081427 Mar 2004 JP
WO 9313706 Jul 1993 WO
WO 9519562 Jul 1995 WO
WO 9834097 Aug 1998 WO
WO 0032262 Jun 2000 WO
WO 0071025 Nov 2000 WO
WO 0116577 Mar 2001 WO
WO 03010510 Feb 2003 WO
WO 2005041765 May 2005 WO
Related Publications (1)
Number Date Country
20080221463 A1 Sep 2008 US